	Applicati n No.	Applicant(s)
Notice of Allowability	10/534,291	COBURN ET AL.
	Examiner	Art Unit
	Yong Chu	1626
	Yong Chu	1020
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to 6/5/2006.		
2. X The allowed claim(s) is/are <u>1,6-9,11-14 and 17</u> .		
<ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> </ul>		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachm nt(s)  1. Notice of References Cited (PTO-892)	5.   Notice of Informat	Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summar	y (PTO-413),
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail Da 08), 7. ⊠ Examiner's Amend	
Paper No./Mail Date  4.  Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Statem	ent of Reasons for Allowance
of Biological Material	9.	

## **DETAILED ACTION**

Claims 2-5, 10, and 15-16 have been canceled by the Supplemental Amendment filed on 10 May 2006. Claims 1, 6, and 17 have been amended by the Supplemental Amendment filed on 5 June 2006. Therefore, Claims 1, 6-9, 11-14, and 17 are pending in this application.

## Response to Amendment

The Supplementary Amendment by Applicants' representative John C. Todaro dated on 5 June 2006 has been entered.

The rejection over claims 1-13 under 35 U.S.C. §112, First Paragraph under Written Description has been withdrawn due to the persuasive argument by Applicants and submission of Declaration under 37 C.F.R §1.132.

The objection over claims 14 and 15 has been withdrawn due to the amendment filed on 5 June 2006.

After considering Amendment filed on 5 June 2006, claims 1, 6-9, 11-14, and 17 are allowed.

## Reasons for Allowance

The present invention relates to a compound of Formula (I)

Application/Control Number: 10/534,291 Page 3

Art Unit: 1626

or a pharmaceutically acceptable salt thereof, a

pharmaceutical composition containing at least one of the said compounds, and a method for treating Alzheimer's disease in a patient comprising administering to the patient a pharmaceutically effective amount of a compound of claim 1. This is a well-defined new class of compounds. The core structure within the scope of search is clear from prior art. The closest prior art of record is co-pending U.S. Patent Application

10/563,538 claiming a compound of formula

inventive entity and assignee. However, one of the key substituents of the core structure is different. Therefore, there is no provisional double patenting found.

The method of treatment of Alzheimer's and pharmaceutical composition claims are supported by the Specification and the disclosed literatures such as *J. Med. Chem.* 2000, 43, 3434-42 by Moore et al., *Arch. Neurol.*, vol. 59 1367-8 by Rosenberg et. al, *J. Med. Chem.* 2002, 59, 16278-284 by Chen et al., as well as the compound inhibiting data submitted in Declaration under 37 C.F.R §1.132.

Therefore, claims 1, 6-9, 11-14, and 17 are allowed.

Art Unit: 1626

## Telephone Inquiry

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Chu whose telephone number is 571-272-5759. The examiner can normally be reached on 7:00 am - 3:30 pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. M<sup>©</sup>Kane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yong Chu, Ph.D. Patent Examiner

Art Unit 1626

KAMAL A. SAEED, PH.D. PRIMARY EXAMINER

Joseph K. M<sup>⊆</sup>Kane

Supervisory Patent Examiner

I Sared

Art Unit 1626